Beta-blockers and glioma: a systematic review of preclinical studies and clinical results

Given the median survival of 15 months after diagnosis, novel treatment strategies are needed for glioblastoma. Beta-blockers have been demonstrated to inhibit angiogenesis and tumor cell proliferation in various cancer types. The aim of this study was to systematically review the evidence on the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Tewarie, Ishaan Ashwini, Senders, Joeky T., Hulsbergen, Alexander F. C., Kremer, Stijn, Broekman, Marike L. D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035104/
https://www.ncbi.nlm.nih.gov/pubmed/32172480
http://dx.doi.org/10.1007/s10143-020-01277-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8035104/
https://www.ncbi.nlm.nih.gov/pubmed/32172480
http://dx.doi.org/10.1007/s10143-020-01277-4

Ejemplares similares